Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JCV vaccine
- Development stage
- Preclinical
- Lead developer
- Belyntic
- Modality
- Peptides, Vaccines & Immunotherapeutics
01
Overview
This preclinical-stage synthetic long peptide vaccine is being developed by Belyntic for the prevention and treatment of John Cunningham virus (JCV) reactivation and Progressive multifocal leukoencephalopathy (PML) in immunocompromised patients. The vaccine utilizes Belyntic's proprietary T-Fender platform technology, which consists of self-adjuvanting, self-aggregating synthetic long peptides designed to elicit robust T cell responses against JCV. By stimulating cellular immunity, the vaccine aims to control JCV infection and prevent the destruction of oligodendrocytes in the brain's white matter, which leads to PML. The development is conducted in collaboration with Charité – Universitätsmedizin Berlin.
- Other names
- John Cunningham virus vaccineBelyntic JCV vaccineT-Fender JCV vaccine
02
Targets
Hla (Staphylococcus aureus alpha toxin)TLR4 (Toll-like receptor 4)TLR7 (Toll-like receptor 7)
Beyond the preview
Go deeper on JCV vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JCV vaccine.